BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olaparib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olaparib\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05093231-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Olaparib: Phase 2 readout est. (NCT05093231)
DESCRIPTION:Olaparib\, phase 2\, Pancreatic Cancer.\nStudy: Pembrolizumab W
 ith Olaparib as Combined Therapy in Metastatic Pancreatic Cancer\nEstimate
 d primary completion: 30 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05093231
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03740893-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 2 readout est. (NCT03740893)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: PHOENIX DDR/Anti-PD
 -L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant
  Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD
 -L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residua
 l Triple Negative Breast Cancer\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03740893
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03375307-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Olaparib: Phase 2 readout est. (NCT03375307)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Testing Olaparib in Patients With A
 dvanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Ge
 nitourinary Tumors With DNA-Repair Genetic Changes\nEstimated primary comp
 letion: 16 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03375307
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03772561-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 1 readout est. (NCT03772561)
DESCRIPTION:Olaparib\, phase 1.\nStudy: Phase I Study of AZD5363 + Olaparib
  + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignan
 cies\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03772561
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585958-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 1 readout est. (NCT04585958)
DESCRIPTION:Olaparib\, phase 1\, Ovarian Cancer.\nStudy: Testing the Combin
 ation of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion i
 n Patients With Platinum Resistant Ovarian Cancer\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04585958
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03594396-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT03594396)
DESCRIPTION:Olaparib\, phase 1/2\, Breast Cancer.\nStudy: Window of Opportu
 nity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or L
 ow ER+ Breast Cancer\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03594396
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 2 readout est. (NCT06739395)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Precision Medicine Trial Based on M
 olecular Matching Therapy for Patients With Standard Treatment Exhaustion\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Canadian Profiling and Targeted Age
 nt Utilization Trial (CAPTUR)\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03297606
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03579316-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olaparib: Phase 2 readout est. (NCT03579316)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Adavosertib With or Without Olapari
 b in Treating Patients With Recurrent Ovarian\, Primary Peritoneal\, or Fa
 llopian Tube Cancer\nEstimated primary completion: 31 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03579316
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04666740-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Olaparib: Phase 2 readout est. (NCT04666740)
DESCRIPTION:Olaparib\, phase 2.\nStudy: A Study of Pembrolizumab and Olapar
 ib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homolog
 ous Recombination Deficiency or Exceptional Treatment Response to Platinum
 -Based Therapy\nEstimated primary completion: January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04666740
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683679-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Olaparib: Phase 2 readout est. (NCT04683679)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Ra
 diosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Posit
 ive/Her2 Negative Breast Cancer\nEstimated primary completion: January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04683679
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05188508-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Olaparib: Phase 2 readout est. (NCT05188508)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Pembrolizumab\, Olaparib\, and Temo
 zolomide for People With Glioma\nEstimated primary completion: January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05188508
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05870423-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Olaparib: Phase 1 readout est. (NCT05870423)
DESCRIPTION:Olaparib\, phase 1.\nStudy: Improving Peptide Receptor Radionuc
 lide Therapy With PARP Inhibitors\nEstimated primary completion: 1 January
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05870423
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03851614-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Olaparib: Phase 2 readout est. (NCT03851614)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Study of DNA Damage\, Angiogenesis\
 , and PD-L1 Inhibitors in Advanced Solid Tumors\nEstimated primary complet
 ion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03851614
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05366166-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:Olaparib: Phase 2 readout est. (NCT05366166)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Pembrolizumab Plus Olaparib in LA-H
 NSCC\nEstimated primary completion: 21 January 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05366166
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371104-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olaparib: Phase 1 readout est. (NCT07371104)
DESCRIPTION:Olaparib\, phase 1\, Ovarian Cancer.\nStudy: Bioequivalence Stu
 dy of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Ca
 ncer\nEstimated primary completion: March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07371104
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03786796-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olaparib: Phase 2 readout est. (NCT03786796)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Study of Olaparib in Metastatic Ren
 al Cell Carcinoma Patients With DNA Repair Gene Mutations\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03786796
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121401-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Olaparib: Phase 4 readout est. (NCT06121401)
DESCRIPTION:Olaparib\, phase 4.\nStudy: First Line Treatment With Olaparib 
 in Combination With Bevacizumab in HRD Positive Patients\nEstimated primar
 y completion: 15 March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06121401
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113964-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Olaparib: Phase 2 readout est. (NCT07113964)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer 
 Patients With Homologous Recombination Deficiency (HRD)\nEstimated primary
  completion: 30 March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07113964
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:Olaparib\, phase 1/2\, Ovarian Cancer.\nStudy: QLS5132 Combinat
 ion Therapy in Advanced Solid Tumors\nEstimated primary completion: April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07453394
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421963-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Olaparib: Phase 3 readout est. (NCT04421963)
DESCRIPTION:Olaparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Roll Over StudY for Patients Who Have Completed a Previous Oncology Stud
 y With Olaparib\nEstimated primary completion: 6 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04421963
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05932862-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Olaparib: Phase 1 readout est. (NCT05932862)
DESCRIPTION:Olaparib\, phase 1.\nStudy: A Phase 1 Study of XL309 (ISM3091) 
 Alone and in Combination in Participants With Advanced Solid Tumors\nEstim
 ated primary completion: 30 April 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05932862
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909825-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Olaparib: Phase 2 readout est. (NCT06909825)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Me
 tastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstimated primary c
 ompletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06909825
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488378-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Olaparib: Phase 1 readout est. (NCT06488378)
DESCRIPTION:Olaparib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and
  PALB2- Associated Metastatic HER2-negative Breast Cancer\nEstimated prima
 ry completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06488378
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04633239-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Olaparib: Phase 1 readout est. (NCT04633239)
DESCRIPTION:Olaparib\, phase 1\, Ovarian Cancer.\nStudy: Testing the Additi
 on of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer\nEst
 imated primary completion: 1 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04633239
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460180-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT07460180)
DESCRIPTION:Olaparib\, phase 1/2\, Ovarian Cancer.\nStudy: The PROOV Study:
  Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and H
 yperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Can
 cer\nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07460180
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Olaparib: Phase 3 readout est. (NCT04380636)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Study of Pembrolizumab With Concurr
 ent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olapa
 rib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-0
 12)\nEstimated primary completion: 5 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04380636
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005583-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Olaparib: Phase 2 readout est. (NCT07005583)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Clinical Study of Q
 L1706 in Combination With Olaparib for the Treatment of Patients With Prev
 iously Treated Homologous Recombination Repair-Deficient Recurrent or Meta
 static Triple-Negative Breast Cancer\nEstimated primary completion: 30 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07005583
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06545942-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Olaparib: Phase 1 readout est. (NCT06545942)
DESCRIPTION:Olaparib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Study of Orally Administered MOMA-313 in Participants With Advanced or M
 etastatic Solid Tumors\nEstimated primary completion: 31 May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06545942
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04005690-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Olaparib: Phase 1 readout est. (NCT04005690)
DESCRIPTION:Olaparib\, phase 1\, Pancreatic Cancer.\nStudy: Targeted Pathwa
 y Inhibition in Patients With Pancreatic Cancer\nEstimated primary complet
 ion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ola
 parib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04005690
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03598257-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Olaparib: Phase 2 readout est. (NCT03598257)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Radiation Therapy With or Without Olaparib in Treating Patients With Inf
 lammatory Breast Cancer\nEstimated primary completion: 1 June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03598257
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03943173-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270627
DTEND;VALUE=DATE:20270628
SUMMARY:Olaparib: Phase 1 readout est. (NCT03943173)
DESCRIPTION:Olaparib\, phase 1\, Ovarian Cancer.\nStudy: Olaparib in Treati
 ng Patients With Newly Diagnosed BRCA-Mutant Ovarian\, Primary Peritoneal\
 , or Fallopian Cancer Before Surgery\nEstimated primary completion: 27 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03943173
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686745-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olaparib: Phase 1 readout est. (NCT06686745)
DESCRIPTION:Olaparib\, phase 1.\nStudy: Study of SIM0508 Alone and in Combi
 nation in Patients With Advanced Solid Tumors\nEstimated primary completio
 n: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olap
 arib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06686745
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03085147-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT03085147)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: A Dye for the Detection of Cancer
  of the Tongue and Mouth\nEstimated primary completion: July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03085147
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623319-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Olaparib: Phase 2 readout est. (NCT05623319)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Pembrolizumab and Olaparib Treatmen
 t of Extensive Small Cell Lung Cancer (ES-SCLC)\nEstimated primary complet
 ion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olapa
 rib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05623319
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524935-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Olaparib: Phase 2 readout est. (NCT05524935)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Olaparib in Combination With Pembro
 lizumab for Advanced Uveal Melanoma\nEstimated primary completion: July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05524935
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05432518-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Olaparib: Phase 1 readout est. (NCT05432518)
DESCRIPTION:Olaparib\, phase 1.\nStudy: Pilot Trial for Treatment of Recurr
 ent Glioblastoma\nEstimated primary completion: 1 July 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05432518
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04086485-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT04086485)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: Lu-177-DOTATATE (Lutathera) in Co
 mbination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocri
 ne Tumors (GEP-NET)\nEstimated primary completion: 1 July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04086485
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05238922-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Olaparib: Phase 1 readout est. (NCT05238922)
DESCRIPTION:Olaparib\, phase 1.\nStudy: Study of INCB123667 in Subjects Wit
 h Advanced Solid Tumors\nEstimated primary completion: 27 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05238922
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169841-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Olaparib: Phase 2 readout est. (NCT04169841)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Study Evaluating the Efficacy of a 
 Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers
  and Carriers of Homologous Recombination Repair Genes After Olaparib Trea
 tment\nEstimated primary completion: 10 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04169841
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04038502-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Olaparib: Phase 2 readout est. (NCT04038502)
DESCRIPTION:Olaparib\, phase 2\, Prostate Cancer.\nStudy: Carboplatin or Ol
 aparib for BRcA Deficient Prostate Cancer\nEstimated primary completion: 3
 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olapar
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4038502
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06298084-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06298084)
DESCRIPTION:Olaparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Dose-Expansion Modular Study To Explore the Safety\, Tolerability\, an
 d Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patient
 s With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd\
 nEstimated primary completion: September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06298084
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olaparib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Olaparib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DRUP
  Trial)\nEstimated primary completion: September 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686030-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olaparib: Phase 2 readout est. (NCT06686030)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: Combination Therap
 y of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian
  Cancer\nEstimated primary completion: October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06686030
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Study of Pembrolizumab (MK-3475) Combination Therapies in
  Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
 \nEstimated primary completion: 22 October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02861573
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624204-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Olaparib: Phase 3 readout est. (NCT04624204)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Placebo-controlled\, Study of Concu
 rrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab 
 and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell 
 Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)\nEstimated primary complet
 ion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04624204
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02484404-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT02484404)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: Phase I/II Study of the Anti-Prog
 rammed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With O
 laparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurre
 nt Ovarian\, Triple Negative Breast\, Lung\, Prostate and Colorectal Can..
 .\nEstimated primary completion: 30 October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02484404
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06217757-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06217757)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: Safety and Tolerability of LDRT+S
 ugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Posit
 ive ES-SCLC\nEstimated primary completion: 31 October 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06217757
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04858334-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olaparib: Phase 2 readout est. (NCT04858334)
DESCRIPTION:Olaparib\, phase 2\, Pancreatic Cancer.\nStudy: APOLLO: A Rando
 mized Phase II Double-Blind Study of Olaparib Versus Placebo Following Cur
 ative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pat
 hogenic BRCA1\, BRCA2 or PALB2 Mutation\nEstimated primary completion: 31 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olapari
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 858334
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933419-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT07933419)
DESCRIPTION:Olaparib\, phase 1/2\, Ovarian Cancer.\nStudy: Phase Ib/II Clin
 ical Study of QLS5133 Combination Therapy in Advanced Solid Tumors\nEstima
 ted primary completion: 15 November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07933419
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900895-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 1 readout est. (NCT05900895)
DESCRIPTION:Olaparib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Estradiol Plus Olaparib for Breast Cancer (PHOEBE)\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05900895
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695259-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Olaparib: Phase 4 readout est. (NCT07695259)
DESCRIPTION:Olaparib\, phase 4\, Breast Cancer.\nStudy: Olaparib+Trastuzuma
 b+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer\nEstimated primar
 y completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07695259
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05568550-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Olaparib: Phase 2 readout est. (NCT05568550)
DESCRIPTION:Olaparib\, phase 2\, Prostate Cancer.\nStudy: Pembro With Radia
 tion With or Without Olaparib\nEstimated primary completion: 2 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05568550
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03741426-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Olaparib: Phase 2 readout est. (NCT03741426)
DESCRIPTION:Olaparib\, phase 2.\nStudy: WIRE - Novel Treatments in Renal Ce
 ll Cancer\nEstimated primary completion: 30 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03741426
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04728230-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT04728230)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: Olaparib and Durvalumab With Carb
 oplatin\, Etoposide\, and/or Radiation Therapy for the Treatment of Extens
 ive-Stage Small Cell Lung Cancer\, PRIO Trial\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04728230
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407452-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT07407452)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: Iparomlimab and Tu
 vonralimab (QL1706) Combined With Standard Chemotherapy or Combined With I
 ntraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy 
 for Advanced Ovarian Cancer\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07407452
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Olaparib\, phase 2.\nStudy: TAPUR: Testing the Use of Food and 
 Drug Administration (FDA) Approved Drugs That Target a Specific Abnormalit
 y in a Tumor Gene in People With Advanced Stage Cancer\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT02693535
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02489006-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT02489006)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: A Study of Olapari
 b Prior to Surgery and Chemotherapy in Ovarian\, Primary Peritoneal\, and 
 Fallopian Tube Cancer\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT02489006
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667751-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT07667751)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: An Exploratory Stu
 dy on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Ola
 parib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07667751
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04090567-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT04090567)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Meta
 static Germline BRCA Mutated Breast Cancer\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ola
 parib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04090567
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06160843-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olaparib: Phase 2 readout est. (NCT06160843)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Pembrolizumab and Olaparib Treatmen
 t for Relapsed or Refractory Peripheral T-Cell Lymphoma\nEstimated primary
  completion: January 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06160843
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02029001-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olaparib: Phase 2 readout est. (NCT02029001)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Adapting Treatment to the Tumor Mol
 ecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificT
 reatment\nEstimated primary completion: January 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02029001
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024784-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olaparib: Phase 2 readout est. (NCT07024784)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: A Study to Assess 
 Change in Disease Activity and Adverse Events in Adult Participants With G
 ynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherap
 y or in Combination With Other Therapies\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0702
 4784
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644289-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olaparib: Phase 2 readout est. (NCT04644289)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: WoO: Window of Opp
 ortunity Trial of Olaparib and Durvalumab in Histologically Proven EOC\nEs
 timated primary completion: January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04644289
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05255471-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280121
DTEND;VALUE=DATE:20280122
SUMMARY:Olaparib: Phase 3 readout est. (NCT05255471)
DESCRIPTION:Olaparib\, phase 3\, Ovarian Cancer.\nStudy: MITO 35B: Olaparib
  Beyond Progression Compared to Platinum Chemotherapy After Secondary Cyto
 reductive Surgery in Recurrent Ovarian Cancer Patients.\nEstimated primary
  completion: 21 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05255471
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177171-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olaparib: Phase 1 readout est. (NCT06177171)
DESCRIPTION:Olaparib\, phase 1.\nStudy: Olaparib and ASTX727 in BRCA1/2- an
 d Homologous Recombination Deficient (HRD)-Mutated Tumors\nEstimated prima
 ry completion: 31 January 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06177171
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652242-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Olaparib: Phase 1 readout est. (NCT07652242)
DESCRIPTION:Olaparib\, phase 1\, Breast Cancer.\nStudy: Phase 1 Study of a 
 Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast
  Cancer\nEstimated primary completion: February 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07652242
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Olaparib: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: A Study Evaluating
  the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Pe
 rsistent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primary co
 mpletion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04931342
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04394858-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Olaparib: Phase 2 readout est. (NCT04394858)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Testing the Addition of an Anticanc
 er Drug\, Olaparib\, to the Usual Chemotherapy (Temozolomide) for Advanced
  Neuroendocrine Cancer\nEstimated primary completion: 1 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04394858
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olaparib: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: Ceralasertib (AZD6738) Alone and in Combination With Olapar
 ib or Durvalumab in Patients With Solid Tumors\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ol
 aparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03682289
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05128734-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Olaparib: Phase 2 readout est. (NCT05128734)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Temozolomide Monoth
 erapy or in Combination With Olaparib in Patients With Triple Negative Bre
 ast Cancer (TNBC)\nEstimated primary completion: 1 April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05128734
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04515836-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Olaparib: Phase 2 readout est. (NCT04515836)
DESCRIPTION:Olaparib\, phase 2.\nStudy: Olaparib in Patients With HRD Malig
 nant Mesothelioma\nEstimated primary completion: 15 April 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04515836
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187674-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Olaparib: Phase na readout est. (NCT07187674)
DESCRIPTION:Olaparib\, phase na\, Breast Cancer.\nStudy: The Neoadjuvant Tr
 eatment of Early High-risk Triple Negative Breast Cancer With HRD Positive
  With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel\n
 Estimated primary completion: 15 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07187674
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02208375-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Olaparib: Phase 1 readout est. (NCT02208375)
DESCRIPTION:Olaparib\, phase 1\, Breast Cancer.\nStudy: mTORC1/2 Inhibitor 
 AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ov
 arian\nEstimated primary completion: 30 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT02208375
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05898399-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT05898399)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: Study of ART6043 in Advanced/Meta
 static Solid Tumors Patients (POLKA)\nEstimated primary completion: 30 Jun
 e 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05898399
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05485766-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Olaparib: Phase 2 readout est. (NCT05485766)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Novel Neoadjuvant a
 nd Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast 
 Cancer\nEstimated primary completion: 30 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05485766
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156253-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280825
DTEND;VALUE=DATE:20280826
SUMMARY:Olaparib: Phase 1 readout est. (NCT07156253)
DESCRIPTION:Olaparib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Study of SYN818 With Olaparib for the Treatment of Locally Advanced or M
 etastatic Solid Tumors\nEstimated primary completion: 25 August 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07156253
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03162627-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Olaparib: Phase 1 readout est. (NCT03162627)
DESCRIPTION:Olaparib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Selumetinib and Olaparib in Solid Tumors\nEstimated primary completion: 
 30 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olapa
 rib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03162627
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952453-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Olaparib: Phase 2 readout est. (NCT05952453)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: Newly Diagnosed St
 age III/IV Ovarian Cancer\, Neoadjuvant Carbo/Taxol/Pembro\, Maintenance O
 laparib/Pembro\nEstimated primary completion: 30 October 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05952453
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Olaparib: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Olaparib\, phase 3\, Breast Cancer.\nStudy: A Phase III Randomi
 sed Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Tre
 atment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Can
 cer\nEstimated primary completion: 20 November 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06746116-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Olaparib: Phase 3 readout est. (NCT06746116)
DESCRIPTION:Olaparib\, phase 3.\nStudy: A Study to Evaluate the Use of Durv
 alumab in Combination With Platinum-based Chemotherapy Followed by Durvalu
 mab With Olaparib as First-line Treatment in Advanced or Recurrent Endomet
 rial Cancer in Spain\nEstimated primary completion: 30 November 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06746116
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641855-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Olaparib: Phase 2/3 readout est. (NCT07641855)
DESCRIPTION:Olaparib\, phase 2/3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of BL-B01D1 Combination Therapy in Patients With 
 Metastatic Castration-resistant Prostate Cancer\nEstimated primary complet
 ion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 laparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07641855
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06201234-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Olaparib: Phase 2 readout est. (NCT06201234)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inh
 ibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer\nEsti
 mated primary completion: 31 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06201234
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684
 )-Based Treatment Combinations or Opevesostat Alone in Participants With M
 etastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)\nEsti
 mated primary completion: 15 January 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05887609-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Olaparib: Phase 2 readout est. (NCT05887609)
DESCRIPTION:Olaparib\, phase 2.\nStudy: An Evaluation of Maintenance Therap
 y Combination Mirvetuximab Soravtansine and Olaparib\nEstimated primary co
 mpletion: 31 January 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05887609
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06245889-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Olaparib: Phase 2 readout est. (NCT06245889)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: PET Dynamics to Res
 ponse-Adapted Neoadjuvant Therapy in TNBC\nEstimated primary completion: J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062458
 89
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607692-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06607692)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: Study in Children and Adolescents
  of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib
  for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somat
 ostatin Receptor (SSTR) (LuPARPed).\nEstimated primary completion: July 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06607692
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976892-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Olaparib: Phase 1 readout est. (NCT06976892)
DESCRIPTION:Olaparib\, phase 1\, Ovarian Cancer.\nStudy: Investigating Idet
 rexed and Olaparib in Patients With Ovarian Cancer\nEstimated primary comp
 letion: December 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06976892
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06856499-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Olaparib: Phase 1 readout est. (NCT06856499)
DESCRIPTION:Olaparib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Rec
 ombination Deficiency Platinum Resistant Ovarian Cancer\nEstimated primary
  completion: 1 December 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06856499
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850973-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT07850973)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: Phase 1/2 Study Of PARP Inhibitio
 n With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refra
 ctory And Relapsed Germ Cell Tumors\nEstimated primary completion: 31 Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07850
 973
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Olaparib: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Study of Patritumab
  Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participant
 s With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Posit
 ive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\nEstim
 ated primary completion: 31 December 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382544-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Olaparib: Phase 1 readout est. (NCT07382544)
DESCRIPTION:Olaparib\, phase 1.\nStudy: Phase 1b Trial of BMS-986504 in Com
 bination With Olaparib in Patients With MTAP Loss\nEstimated primary compl
 etion: 31 January 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07382544
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Olaparib: Phase 2 readout est. (NCT05332561)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Genomics Guided Tar
 geted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNI
 TION-GUIDE)\nEstimated primary completion: March 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712472-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Olaparib: Phase 3 readout est. (NCT06712472)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Randomized Phase III Trial Testing 
 Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for 
 p53abn Endometrial Cancer\nEstimated primary completion: June 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06712472
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Olaparib: Phase 2 readout est. (NCT05564377)
DESCRIPTION:Olaparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Targeted Therapy Directed by Genetic Testing in Treating Patients With L
 ocally Advanced or Advanced Solid Tumors\, The ComboMATCH Screening Trial\
 nEstimated primary completion: 1 July 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05564377
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05522491-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Olaparib: Phase 2 readout est. (NCT05522491)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Olaparib in the Tre
 atment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Me
 tastatic Triple-negative Breast Cancer\nEstimated primary completion: 1 Se
 ptember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olapari
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 522491
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Olaparib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: I-SPY TRIAL: Neoadj
 uvant and Personalized Adaptive Novel Agents to Treat Breast Cancer\nEstim
 ated primary completion: December 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Olaparib\, phase 1/2.\nStudy: European Proof-of-Concept Therape
 utic Stratification Trial of Molecular Anomalies in Relapsed or Refractory
  Tumors\nEstimated primary completion: February 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647653-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Olaparib: Phase 2 readout est. (NCT07647653)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: Fluzoparib + Bevac
 izumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive A
 dvanced Ovarian Cancer\nEstimated primary completion: 28 February 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07647653
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06915025-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Olaparib: Phase 3 readout est. (NCT06915025)
DESCRIPTION:Olaparib\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Trial Eval
 uating the Safety & Efficacy of IMNN-001 Administered in Combination w/ St
 andard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advance
 d EOC\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated primary com
 pletion: 31 October 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06915025
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938645-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20330131
DTEND;VALUE=DATE:20330201
SUMMARY:Olaparib: Phase 2 readout est. (NCT07938645)
DESCRIPTION:Olaparib\, phase 2.\nStudy: PARP Inhibition for Biliary Tract C
 ancer With Mutations in Core and Non-Core Homologous Recombination Deficie
 ncy Genes\nEstimated primary completion: January 2033. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07938645
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Olaparib: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Olaparib\, phase 3\, Breast Cancer.\nStudy: A Clinical Study of
  Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With Breast Cancer 
 (MK-2870-032)\nEstimated primary completion: 23 March 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06966700
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06580314-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Olaparib: Phase 3 readout est. (NCT06580314)
DESCRIPTION:Olaparib\, phase 3\, Ovarian Cancer.\nStudy: Testing Olaparib f
 or One or Two Years\, With or Without Bevacizumab\, to Treat Ovarian Cance
 r\nEstimated primary completion: 31 December 2034. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06580314
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03486873-2028@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20430804
DTEND;VALUE=DATE:20430805
SUMMARY:Olaparib: Phase 3 readout est. (NCT03486873)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Long-term Safety and Efficacy Exten
 sion Study for Participants With Advanced Tumors Who Are Currently on Trea
 tment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYN
 OTE-587)\nEstimated primary completion: 4 August 2043. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03486873
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
